Gyala Therapeutics

Gyala Therapeutics, founded in May 2020 as a spin off of the Hospital Clínic de Barcelona and Institut d'Investigacions Biomediques August Pi i Sunyer (IDIBAPS), is a biotechnology company focused on developing CAR-T cell therapies for the potential treatment of hematological malignanciesIn September 2021, the company raised EUR 1.5 million of seed financing from Invivo Ventures.Gyala Therapeutics 正在开发下一代免疫疗法，用于治疗需求未得到满足的血液癌症。其牵头项目 GYA01 是一种针对 CD84 的同类首创 CAR-T 疗法，CD84 是一种在 AML、T-ALL 和其他血癌中过度表达的蛋白质。